(ser ta KOE na zole)
- Sertaconazole Nitrate
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External, as nitrate:
Ertaczo: 2% (60 g) [contains methylparaben]
Brand Names: U.S.
- Antifungal Agent, Imidazole Derivative
- Antifungal Agent, Topical
Alters fungal cell wall membrane permeability; inhibits the CYP450-dependent synthesis of ergosterol
Topical: Minimal; serum concentrations below the limit of quantitation (<2.5 ng/mL)
Use: Labeled Indications
Tinea pedis: For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
There are no contraindications listed in the manufacturer's labeling.
Tinea pedis: Topical: Apply between toes and to surrounding healthy skin twice daily for 4 weeks
Refer to adult dosing.
Tinea pedis: Topical: Children ≥12 years and Adolescents: Refer to adult dosing.
For external use only. Apply to affected area between toes and to surrounding healthy skin. Make sure skin is dry before applying; wash hands after application. Avoid use of occlusive dressing. Avoid contact with eyes, nose, mouth, and other mucous membranes.
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
There are no known significant interactions.
1% to 10%: Dermatologic: Burning sensation of skin, contact dermatitis, skin tenderness, xeroderma
<1% (Limited to important or life-threatening): Desquamation, erythema, hyperpigmentation, pruritus, skin vesicle
Concerns related to adverse effects:
• Irritation: Discontinue drug if sensitivity or irritation occurs.
• Appropriate use: For topical use only; avoid ophthalmologic, oral, or intravaginal use. Re-evaluate use if no response within 2 weeks.
Reassess diagnosis if no clinical improvement after 2 weeks.
Pregnancy Risk Factor
Adverse events were not observed in animal reproduction studies following oral administration.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience dry skin. Have patient report immediately to prescriber yeast infection, skin discoloration, burning, or severe skin irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.